" class="no-js "lang="en-US"> Charles River & Purespring Announce Gene Therapy Collaboration
Tuesday, April 23, 2024

Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration

Charles River Laboratories International and Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.

Supporting the first gene therapy platform targeting renal diseases, which affect approximately 840 million people, or around 10 percent of the global population, the program leverages Charles River’s established plasmid platform, eXpDNA™, and decades of experience at the Company’s plasmid DNA manufacturing center of excellence.

Purespring is engaged in the development of novel therapies which have the potential to stop or significantly slow down chronic kidney diseases for which there is no current therapy available, except for dialysis or transplantation. With an innovative focus on the podocyte, a specialized kidney cell type implicated in many kidney diseases, Purespring’s Adeno Associated Virus (AAV) based gene therapy presents a lower-dose, local delivery approach which maximizes both safety and efficacy, as well as lowering the cost of goods.

Expanding its comprehensive cell and gene therapy portfolio to span plasmid DNA, viral vector, and cell therapy production, through the acquisitions of Cobra Biologics, Vigene Biosciences, and Cognate BioServices in 2021, and in addition to recent expansion projects, Charles River offers end-to-end support and supply chain simplification for developers seeking to accelerate their program while ensuring the highest quality control. The eXpDNA plasmid manufacturing platform builds on Charles River’s proven plasmid DNA CDMO capabilities and processes, fine-tuned over decades successfully supporting vaccine and advanced therapy clients through clinical trials and beyond.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more